Alphatec (NASDAQ:ATEC – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.
Valuation & Earnings
This table compares Alphatec and Sight Sciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alphatec | $540.28 million | 1.36 | -$186.64 million | ($1.49) | -3.54 |
| Sight Sciences | $81.06 million | 3.35 | -$55.55 million | ($1.07) | -5.04 |
Sight Sciences has lower revenue, but higher earnings than Alphatec. Sight Sciences is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Alphatec | -33.48% | -816.57% | -23.97% |
| Sight Sciences | -65.90% | -45.68% | -32.27% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Alphatec and Sight Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alphatec | 0 | 1 | 8 | 0 | 2.89 |
| Sight Sciences | 0 | 4 | 1 | 0 | 2.20 |
Alphatec currently has a consensus price target of $17.00, suggesting a potential upside of 222.58%. Sight Sciences has a consensus price target of $7.25, suggesting a potential upside of 34.51%. Given Alphatec’s stronger consensus rating and higher probable upside, analysts clearly believe Alphatec is more favorable than Sight Sciences.
Insider and Institutional Ownership
66.3% of Alphatec shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 22.8% of Alphatec shares are owned by insiders. Comparatively, 28.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Alphatec has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500.
Summary
Alphatec beats Sight Sciences on 8 of the 14 factors compared between the two stocks.
About Alphatec
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.
